Erschienen in:
10.08.2022 | Pancreatic Tumors
Survival Benefit of Neoadjuvant Therapy for Extrahepatic Cholangiocarcinoma: Real or Artifact?
verfasst von:
Rebecca A. Snyder, MD, MPH, FSSO
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 1/2023
Einloggen, um Zugang zu erhalten
Excerpt
In the absence of prospective clinical trials, the role of neoadjuvant therapy for non-pancreatic periampullary cancers remains poorly defined. Just this past year, the first clinical trial to compare perioperative chemotherapy versus upfront surgery followed by adjuvant chemotherapy in patients with pancreatic adenocarcinoma was activated (Alliance A021806; NCT04340141). However, designing a similar trial for periampullary malignancies has been fraught with challenges, including a relatively low incidence of these malignancies, preoperative diagnostic uncertainty, heterogeneity across tumor types, and limited data supporting the role of adjuvant therapy in this patient population. …